DK0808162T3 - Anvendelse af carbazolforbindelser til behandling af kongestiv hjertesvigt - Google Patents

Anvendelse af carbazolforbindelser til behandling af kongestiv hjertesvigt

Info

Publication number
DK0808162T3
DK0808162T3 DK96902984T DK96902984T DK0808162T3 DK 0808162 T3 DK0808162 T3 DK 0808162T3 DK 96902984 T DK96902984 T DK 96902984T DK 96902984 T DK96902984 T DK 96902984T DK 0808162 T3 DK0808162 T3 DK 0808162T3
Authority
DK
Denmark
Prior art keywords
heart failure
congestive heart
carbazole compounds
treat congestive
carvedilol
Prior art date
Application number
DK96902984T
Other languages
Danish (da)
English (en)
Inventor
Gisbert Sponer
Klaus Strein
Mary Ann Lukas-Laskey
Robert Ruffolo Jr
Neil Shusterman
Original Assignee
Boehringer Mannheim Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26012210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0808162(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1995103995 external-priority patent/DE19503995C2/de
Application filed by Boehringer Mannheim Pharm Corp filed Critical Boehringer Mannheim Pharm Corp
Application granted granted Critical
Publication of DK0808162T3 publication Critical patent/DK0808162T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK96902984T 1995-02-08 1996-02-07 Anvendelse af carbazolforbindelser til behandling af kongestiv hjertesvigt DK0808162T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1995103995 DE19503995C2 (de) 1995-02-08 1995-02-08 Verwendung von Carvedilol zur Verminderung der Mortalität bei Patienten mit eingeschränkter myocardialer Funktion
US08/483,635 US5760069A (en) 1995-02-08 1995-06-07 Method of treatment for decreasing mortality resulting from congestive heart failure
PCT/EP1996/000498 WO1996024348A2 (en) 1995-02-08 1996-02-07 Use of carbazole compounds for the treatment of congestive heart failure

Publications (1)

Publication Number Publication Date
DK0808162T3 true DK0808162T3 (da) 1999-11-15

Family

ID=26012210

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96902984T DK0808162T3 (da) 1995-02-08 1996-02-07 Anvendelse af carbazolforbindelser til behandling af kongestiv hjertesvigt

Country Status (27)

Country Link
US (6) US5760069A (ru)
EP (1) EP0808162B1 (ru)
JP (1) JP3546058B2 (ru)
KR (1) KR100295940B1 (ru)
CN (1) CN1093760C (ru)
AT (1) ATE179891T1 (ru)
AU (1) AU702106C (ru)
BR (1) BR9607111A (ru)
CA (1) CA2212548C (ru)
CZ (1) CZ292002B6 (ru)
DE (1) DE69602424T2 (ru)
DK (1) DK0808162T3 (ru)
ES (1) ES2134588T3 (ru)
FI (1) FI973255A0 (ru)
GR (1) GR3030966T3 (ru)
HK (1) HK1014861A1 (ru)
HU (1) HUP9900773A3 (ru)
NO (1) NO314830B1 (ru)
NZ (1) NZ301692A (ru)
PL (1) PL321737A1 (ru)
RO (1) RO121629B1 (ru)
RU (1) RU2197242C2 (ru)
SI (1) SI0808162T1 (ru)
SK (1) SK106897A3 (ru)
UA (1) UA55382C2 (ru)
WO (1) WO1996024348A2 (ru)
ZA (1) ZA96994B (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
CA2267967A1 (en) * 1996-10-09 1998-04-16 Boehringer Mannheim Pharmaceuticals Corp. - Smithkline Beecham Corporati On Limited Partnership No.1 Method for inhibiting stress-activated protein kinases
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
IL136028A0 (en) * 1997-11-12 2001-05-20 Boehringer Mannheim Pharm Corp Novel oral dosage form for carvedilol
US6664284B2 (en) 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
DE19833119A1 (de) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
WO2001017528A1 (en) * 1999-09-08 2001-03-15 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
DE60042611D1 (de) * 1999-10-29 2009-09-03 Nitromed Inc Verfahren zur behandlung von gefässerkrankungen, dxid auszeichnen
US7708989B2 (en) * 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7537785B2 (en) * 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
US7235237B2 (en) * 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
PL365694A1 (en) * 2000-06-28 2005-01-10 Teva Pharmaceutical Industries Ltd. Carvedilol
JP2004525941A (ja) * 2001-04-02 2004-08-26 スミスクライン・ビーチャム・コーポレイション 治療方法
WO2003028718A1 (en) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Novel formulations of carvedilol
WO2003028649A2 (en) * 2001-10-02 2003-04-10 Smithkline Beecham Corporation Novel composition of carvedilol
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
SE0103749D0 (sv) * 2001-11-08 2001-11-08 Sahltech Ab Treatment of congestive heart failure
US6710184B2 (en) * 2002-01-15 2004-03-23 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
EP1499310A4 (en) * 2002-04-30 2005-12-07 Sb Pharmco Inc MONOCITRATE MONOHYDRATE OF CARVEDILOL
US6951880B2 (en) * 2002-05-16 2005-10-04 Genelabs Technologies, Inc. Aryl and heteroaryl compounds as antibacterial and antifungal agents
AU2003251627A1 (en) * 2002-06-27 2004-01-19 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
MXPA04012923A (es) * 2002-06-27 2005-03-31 Sb Pharmco Inc Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento.
DE60200160T2 (de) * 2002-07-25 2004-11-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
US20050032879A1 (en) * 2003-08-07 2005-02-10 Temple Okarter Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
EP1691789B1 (en) * 2003-11-25 2017-12-20 SmithKline Beecham (Cork) Limited Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US20060014829A1 (en) * 2004-07-16 2006-01-19 Nitromed, Inc. Methods for reducing hospitalizations related to heart failure
US20070043099A1 (en) * 2005-06-09 2007-02-22 Igor Lifshitz Crystalline forms of carvedilol and processes for their preparation
US20080293724A1 (en) * 2006-02-17 2008-11-27 Nitromed, Inc. Methods Using Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US8703804B2 (en) * 2006-03-26 2014-04-22 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
WO2007136626A1 (en) * 2006-05-16 2007-11-29 Nitromed, Inc. Solid dosage formulations of hydralazine compounds
WO2008002683A2 (en) * 2006-06-28 2008-01-03 Teva Pharmaceutical Industries Ltd. Polymorphous forms of carvedilol phosphate
EP2114881A1 (en) * 2007-02-26 2009-11-11 Teva Pharmaceutical Industries Ltd. Process for the purification of carvedilol or its salts thereof
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
GB2462221B (en) 2008-05-16 2010-09-01 Corthera Inc Administration of relaxin to reduce diuretic use in humans with acute decompensated heart failure
CA3215310A1 (en) 2010-04-12 2011-10-20 Supernus Pharmaceuticals Inc. Methods for producing viloxazine salts and novel polymorphs thereof
RU2014109079A (ru) 2011-08-12 2015-09-20 Бёрингер Ингельхайм Ветмедика Гмбх Фармацевтическая композиция с маскированным вкусом
US20170354592A1 (en) * 2016-06-13 2017-12-14 Ascendia Pharmaceuticals, Llc Parenteral sustained-release delivery of carvedilol disperse systems
US10772869B1 (en) 2019-07-24 2020-09-15 ECI Pharmaceuticals, LLC Pharmaceutical compositions including carvedilol and methods of using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
SE460945B (sv) * 1987-01-15 1989-12-11 Lejus Medical Ab En multipel-unit-dos komposition av furosemid
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure

Also Published As

Publication number Publication date
EP0808162A2 (en) 1997-11-26
US20030105138A1 (en) 2003-06-05
AU702106C (en) 2005-02-17
KR19980702085A (ko) 1998-07-15
USRE40707E1 (en) 2009-05-05
MX9706042A (es) 1998-06-30
ATE179891T1 (de) 1999-05-15
EP0808162B1 (en) 1999-05-12
NZ301692A (en) 2000-09-29
WO1996024348A3 (en) 1996-10-03
CN1093760C (zh) 2002-11-06
CZ292002B6 (cs) 2003-07-16
USRE40000E1 (en) 2008-01-08
JP3546058B2 (ja) 2004-07-21
FI973255A (fi) 1997-08-07
US5902821A (en) 1999-05-11
KR100295940B1 (ko) 2001-08-07
ZA96994B (en) 1997-10-27
SI0808162T1 (en) 1999-10-31
CA2212548A1 (en) 1996-08-15
HK1014861A1 (en) 1999-10-08
NO973667D0 (no) 1997-08-08
CN1185106A (zh) 1998-06-17
ES2134588T3 (es) 1999-10-01
DE69602424D1 (de) 1999-06-17
SK106897A3 (en) 1999-03-12
CA2212548C (en) 1999-08-24
NO973667L (no) 1997-08-08
UA55382C2 (ru) 2003-04-15
RO121629B1 (ro) 2008-01-30
HUP9900773A2 (hu) 1999-07-28
BR9607111A (pt) 1997-11-04
WO1996024348A2 (en) 1996-08-15
HUP9900773A3 (en) 2000-04-28
CZ246397A3 (cs) 1998-11-11
NO314830B1 (no) 2003-06-02
JPH10513463A (ja) 1998-12-22
PL321737A1 (en) 1997-12-22
FI973255A0 (fi) 1997-08-07
US5760069A (en) 1998-06-02
DE69602424T2 (de) 1999-10-07
AU4718196A (en) 1996-08-27
AU702106B2 (en) 1999-02-11
RU2197242C2 (ru) 2003-01-27
US20010044455A1 (en) 2001-11-22
GR3030966T3 (en) 1999-11-30

Similar Documents

Publication Publication Date Title
DK0808162T3 (da) Anvendelse af carbazolforbindelser til behandling af kongestiv hjertesvigt
NO20013727D0 (no) Anvendelse av Botulinumtoksin B for fremstilling av et medikament
DK0869808T3 (da) Anvendelse af Glu-Trp-dipeptider til fremstilling af et lægemiddel til behandling af forskellige tilstande, der involverer neovaskularisation
DE60322102D1 (de) Transdermales buprenorphin-dosierschema zwecks schmerzstillung
MX9602442A (es) Un tratamiento con fluoroquinolona a dosis unica elevada.
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
ES2158996T3 (es) Agonistas beta3 adrenergicos selectivos.
EA199800866A1 (ru) Способ снятия боли
DE69227583D1 (de) Arylmorpholine, herstellung und verwendung
DE69218200D1 (de) Behandlung von leberkrebs
HUP9801925A1 (hu) Nátrium/hidrogén-csere inhibítorok alkalmazása protozoák által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
AU4578501A (en) Method for treating congestive heart failure
DK0703781T3 (da) Anvendelse af Efaroxan og derivater deraf til fremstilling af et lægemiddel til behandling af Parkinsons sygdom
ATE207353T1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
PT1305020E (pt) Utilizacao de fibratos para a preparacao de um medicamento util no tratamento da insuficiencia cardiaca congestiva
FR2416890A1 (fr) Derives de 1,5-benzothiazepines, leur preparation et leurs utilisations therapeutiques
UA10754A (ru) Способ терапии артериальных гипертензий разного генеза
ATE74505T1 (de) Schmerzpraeparat.
UA36762A (uk) Спосіб лікування хворих на обмежену склеродермію
OA09519A (fr) D-acide aspartique b-hydroxamate en tant que medicament
UA22022A (ru) Способ лечения больных с высоким риском развития полиоргаhhой hедостаточности
HUP9802142A2 (hu) Na+/H+ -ioncsere inhibítorok alkalmazása a központi idegrendszer betegségeinek kezelésére és megelőzésére alkalmas gyógyszerkészítmények előállítására
DE69909097D1 (de) 5-bicycloindolverbindungen
NZ336321A (en) Use of benzothiophene (raloxifene) for treating breast cancer
RU92001939A (ru) Способ лечения псориаза